CompanyTVTXNasdaqSan Diego, CA

Travere Therapeutics, Inc.

Travere Therapeutics develops therapies for rare kidney and metabolic diseases.

SEC EDGAR ClinicalTrials.gov ir.travere.com

8-KSep 21Latest SEC filing, period to Sep 21

Sep 21Latest story

September 2026

Travere Therapeutics names Bradley Campbell CEO as Eric Dube exits

Sep 21PeopleTravere Therapeutics, Inc.

August 2026

Travere reports Q2 2026 results as FSGS launch begins and civorebrutinib deal closes

Aug 4Quarterly updatepegtibatinase sparsentan

July 2026

Travere's chief accounting officer to retire, controller named as successor

Jul 9PeopleTravere Therapeutics, Inc.